Here Is A New Class Of RNA Therapeutics
The approval in 2018 of a new drug to treat polyneuropathy caused by a rare and frequently fatal disease called hereditary transthyretin-mediated amyloidosis (hATTR) marks the arrival of a new class of therapeutics. The new drug, called patisiran (Onpattro), is a small interfering RNA (siRNA) that is part of a class of therapeutics that can … Read more